Exicure (Nasdaq:XCUR) - Aktienkurs, Nachrichten und Analyse

XCUR Aktienübersicht

Exicure, Inc. hat keine nennenswerte Geschäftstätigkeit.

XCUR grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	0/6
Künftiges Wachstum	0/6
Vergangene Leistung	0/6
Finanzielle Gesundheit	1/6
Dividenden	0/6

Belohnungen

Risikoanalyse

Hat weniger als 1 Jahr Cash Runway

Hat keine nennenswerte Marktkapitalisierung ($3M)

Erzielt weniger als 1 Million USD an Einnahmen ($500K)

Stark schwankender Aktienkurs in den letzten 3 Monaten

Exicure, Inc. Wettbewerber

Marizyme

OTCPK:MRZM

US$6.6m

Xenetic Biosciences

NasdaqCM:XBIO

US$6.0m

Mainz Biomed

NasdaqCM:MYNZ

US$4.7m

Bionomics

NasdaqGM:BNOX

US$8.4m

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für Exicure
Historische Aktienkurse
Aktueller Aktienkurs	US$3.64
52-Wochen-Hoch	US$6.00
52-Wochen-Tief	US$1.44
Beta	1.24
11 Monat Veränderung	64.71%
3 Monate Veränderung	127.50%
1 Jahr Veränderung	1.11%
33 Jahre Veränderung	-97.91%
5 Jahre Veränderung	-98.99%
Veränderung seit IPO	-99.22%

Aktuelle Nachrichten und Updates

Recent updates

Little Excitement Around Exicure, Inc.'s (NASDAQ:XCUR) Revenues As Shares Take 25% Pounding

Aug 29

Exicure to get $5.4M equity financing, reduce workforce & end R&D, preclinical activities

Sep 26

Exicure Q2 GAAP loss per share narrows, revenue up

Aug 15

Exicure regains compliance with Nasdaq's minimum bid price requirement

Jul 20

Exicure slides 31% as it implements reverse-stock-split to get back Nasdaq compliance

Jun 29

Aktionärsrenditen

	XCUR	US Biotechs	US Markt
7D	-13.9%	-3.0%	0.9%
1Y	1.1%	19.2%	32.4%

Rendite im Vergleich zur Industrie: XCUR unter dem Niveau der Branche US Biotechs , die im vergangenen Jahr eine Rendite von 14% erzielte.

Rendite vs. Markt: XCUR hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 22.9 erzielte.

Preisvolatilität

Is XCUR's price volatile compared to industry and market?
XCUR volatility
XCUR Average Weekly Movement	39.9%
Biotechs Industry Average Movement	10.0%
Market Average Movement	6.4%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	3.2%

Stabiler Aktienkurs: XCURDer Aktienkurs des Unternehmens war in den letzten 3 Monaten unbeständig.

Volatilität im Zeitverlauf: XCURDie wöchentliche Volatilität der Aktie ist im vergangenen Jahr von 18% auf 27% gestiegen.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
2011	5	Paul Kang	www.exicuretx.com

Bisher konzentrierte sich das Unternehmen auf die Entwicklung von Nukleinsäuretherapien, die auf Ribonukleinsäure gegen validierte Ziele abzielen. Exicure, Inc. wurde im Jahr 2011 gegründet und hat seinen Hauptsitz in Chicago, Illinois.

Exicure, Inc.'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Exicure im Vergleich zum Marktanteil des Unternehmens?
XCUR grundlegende Statistiken
Marktanteil	US$6.59m
Gewinn(TTM)	-US$8.17m
Umsatz(TTM)	US$500.00k

12.6x

Kurs-Umsatz-Verhältnis

-0.8x

Kurs-Gewinn-Verhältnis

Ist XCUR zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
XCUR Gewinn- und Verlustrechnung (TTM)
Einnahmen	US$500.00k
Kosten der Einnahmen	US$0
Bruttogewinn	US$500.00k
Sonstige Ausgaben	US$8.67m
Umsatz	-US$8.17m

Zuletzt gemeldete Gewinne

Jun 30, 2024

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	-4.72
Bruttomarge	100.00%
Nettogewinnspanne	-1,634.40%
Schulden/Eigenkapital-Verhältnis	62.0%

Wie hat sich XCUR auf lange Sicht entwickelt?

Historische Performance und Vergleiche

XCUR Aktienübersicht

Belohnungen

Risikoanalyse

Exicure, Inc. Wettbewerber

OTCPK:MRZM

US$6.6m

NasdaqCM:XBIO

US$6.0m

NasdaqCM:MYNZ

US$4.7m

NasdaqGM:BNOX

US$8.4m

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Nasdaq Hearings Panel Grants Exicure Extension for Continued Listing on The Nasdaq Capital Market, Compliance Required by November 14, 2024

Exicure Regains Compliance with the Minimum Bid Price Requirement Under Nasdaq Listing Rule 5550(a)(2)

Exicure Announces 1-for-5 Reverse Stock Split to Regain Compliance with Nasdaq’s Listing Rules

High number of new and inexperienced directors

Exicure, Inc. Appoints Anna Chukaeva as Senior Vice President, Head of Corporate Development and Bioinformatics

Exicure Receives Positive Listing Determination from Nasdaq

Recent updates

Nasdaq Hearings Panel Grants Exicure Extension for Continued Listing on The Nasdaq Capital Market, Compliance Required by November 14, 2024

Exicure Regains Compliance with the Minimum Bid Price Requirement Under Nasdaq Listing Rule 5550(a)(2)

Exicure Announces 1-for-5 Reverse Stock Split to Regain Compliance with Nasdaq’s Listing Rules

High number of new and inexperienced directors

Exicure, Inc. Appoints Anna Chukaeva as Senior Vice President, Head of Corporate Development and Bioinformatics

Exicure Receives Positive Listing Determination from Nasdaq

Exicure Receives Non-Compliance Letter Regarding Nasdaq Listing Rule 5550(b)(1)

Exicure, Inc., Annual General Meeting, Jun 28, 2024

Exicure, Inc. Receives Nasdaq Notice of A Delisting Determination

Exicure, Inc. announced delayed 10-Q filing

Exicure, Inc. announced delayed annual 10-K filing

New minor risk - Financial data availability

No independent directors

Exicure Receives Non-Compliance Notice From Nasdaq

Exicure Receives Nasdaq Delinquency Notice on Late Filing of its Form 10-Q

Exicure, Inc. announced delayed 10-Q filing

Exicure, Inc. Appoints Minhee Eom to the Board

Exicure Receives Non-Compliance Notice From Nasdaq

Little Excitement Around Exicure, Inc.'s (NASDAQ:XCUR) Revenues As Shares Take 25% Pounding

Exicure, Inc. Announces Executive Changes

Less than half of directors are independent

Exicure Notifies Nasdaq Regarding Continued to be Not in Compliance with Rule 5605(c)(2)(A)

Exicure Receives Nasdaq Delinquency Notice on Late Filing of its Form 10-Q

CBI USA Inc Sends a Letter to Exicure Inc

Exicure, Inc. announced delayed 10-Q filing

No independent directors

Exicure, Inc. Announces Resignation of Jeffrey L. Cleland from the Board of Directors, Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee

Exicure Receives Notice from Nasdaq Regarding No Longer in Compliance with Nasdaq's Independent Director and Audit Committee Requirements

Exicure, Inc. Announces Resignation of Jiyoung Hwang from the Board of Directors

Exicure, Inc. Announces Executive Changes

Exicure, Inc. Contemplates Bankruptcy

Exicure, Inc. announced that it expects to receive $5.44 million in funding from CBI Inc.

Exicure to get $5.4M equity financing, reduce workforce & end R&D, preclinical activities

Exicure Receives Noncompliance Notice from Nasdaq

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Exicure Q2 GAAP loss per share narrows, revenue up

Exicure Regains Compliance with Nasdaq Minimum Bid Price Requirement

Exicure regains compliance with Nasdaq's minimum bid price requirement

Exicure Announces Receipt of Nasdaq Notice of Non-Compliance

Exicure slides 31% as it implements reverse-stock-split to get back Nasdaq compliance

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Exicure, Inc. announced that it expects to receive $5.040289 million in funding from CBI USA, Inc, Abingworth LLP

High number of new and inexperienced directors

Exicure, Inc., Annual General Meeting, May 27, 2022

Exicure, Inc. Announces Executive, Board and Committee Changes

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Exicure, Inc. Investors

Exicure Receives A Letter from the Staff Nasdaq Stock Market

Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Exicure, Inc

Price target decreased to US$6.75

Does Exicure (NASDAQ:XCUR) Have A Healthy Balance Sheet?

Consensus revenue estimates increase to US$12.9m

Second quarter 2021 earnings released: US$0.16 loss per share (vs US$0.049 loss in 2Q 2020)

Consensus revenue estimates increase to US$22.1m

Price target decreased to US$9.00

Exicure, Inc.(NasdaqCM:XCUR) dropped from Russell Microcap Value Index

Consensus revenue estimates fall to US$5.77m

Price target decreased to US$9.60

Exicure, Inc. Advances Clinical and Pre-Clinical Pipeline Designed to Bring Therapies to Patients with Unmet Medical Needs

First quarter 2021 earnings released: US$0.14 loss per share (vs US$0.013 profit in 1Q 2020)

Erträge & Einnahmen